The USPSTF's grade D recommendation contradicts the common view that PSA screening saves lives by reducing the risk of death from prostate cancer. Decisions about screening should be made by informed patients and their clinicians, weighing particular risk factors.
No takes yet. Share an insight, caveat, or question.
Fritz H. Schröder (2011) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: